BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15013920)

  • 1. The RTOG Outcomes Model: economic end points and measures.
    Konski A; Watkins-Bruner D;
    Expert Opin Pharmacother; 2004 Mar; 5(3):513-9. PubMed ID: 15013920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes research in cancer clinical trial cooperative groups: the RTOG model.
    Bruner DW; Movsas B; Konski A; Roach M; Bondy M; Scarintino C; Scott C; Curran W
    Qual Life Res; 2004 Aug; 13(6):1025-41. PubMed ID: 15287270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04.
    Owen JB; Grigsby PW; Caldwell TM; Konski AA; Johnson DJ; Demas WF; Movsas B; Jones CU; Wasserman TH
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):633-9. PubMed ID: 11172943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
    Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes research in cancer symptom management trials: the Radiation Therapy Oncology Group (RTOG) conceptual model.
    Bruner DW
    J Natl Cancer Inst Monogr; 2007; (37):12-5. PubMed ID: 17951225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation Oncology Clinical Trial Design: An Opportunity to Evaluate Value.
    Shah C; Ward M; Singer ME
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):674-675. PubMed ID: 31540597
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer.
    Fu KK; Cooper JS; Marcial VA; Laramore GE; Pajak TF; Jacobs J; Al-Sarraf M; Forastiere AA; Cox JD
    Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):425-38. PubMed ID: 8655364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic endpoints in clinical trials.
    Cook J; Drummond M; Heyse JF
    Stat Methods Med Res; 2004 Apr; 13(2):157-76. PubMed ID: 15068259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Health Economics in Radiation Oncology: A Systematic Review.
    Nguyen TK; Goodman CD; Boldt RG; Warner A; Palma DA; Rodrigues GB; Lock MI; Mishra MV; Zaric GS; Louie AV
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1006-14. PubMed ID: 26883562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer.
    Byhardt RW
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1513-25. PubMed ID: 7635796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
    Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
    Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.
    Marcial VA; Pajak TF; Kramer S; Davis LW; Stetz J; Laramore GE; Jacobs JR; Al-Sarraf M; Brady LW
    Semin Oncol; 1988 Feb; 15(1):39-60. PubMed ID: 3278390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer.
    Timmerman R; Galvin J; Michalski J; Straube W; Ibbott G; Martin E; Abdulrahman R; Swann S; Fowler J; Choy H
    Acta Oncol; 2006; 45(7):779-86. PubMed ID: 16982540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton therapy of cancer: potential clinical advantages and cost-effectiveness.
    Lundkvist J; Ekman M; Ericsson SR; Jönsson B; Glimelius B
    Acta Oncol; 2005; 44(8):850-61. PubMed ID: 16332592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
    Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.